Results 11 to 20 of about 25,219 (211)

PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST

Рациональная фармакотерапия в кардиологии, 2015
Apixaban is a "new" oral anticoagulant, direct Xa factor inhibitor with a good evidence base of the efficacy in the prevention of ischemic stroke in patients with atrial fibrillation.
D. A. Sychev, I. I. Sinitsina, G. Yu. Zakharova, M. I. Savel'eva, A. V. Ryabova, A. V. Kryukov, A. Yu. Yurovskii   +6 more
doaj   +3 more sources

Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease

Frontiers in Cardiovascular Medicine, 2021
Background and Objectives: Real-world evidence of apixaban treatment in patients with chronic kidney disease remains scarce. This study aimed to compare the relative risk of stroke or systemic embolism (SE) and major bleeding between apixaban and ...
Chung-Ming Fu, Lung-Chih Li, Lung-Chih Li, Yueh-Ting Lee, Shih-Wei Wang, Chien-Ning Hsu, Chien-Ning Hsu   +6 more
doaj   +1 more source

A study on indices of apixaban anticoagulation: A single-center prospective study

Journal of Pharmacological Sciences, 2018
Background: Depending on the characteristics of patients, the blood concentration of apixaban can unexpectedly increase, possibly leading to bleeding events.
Maki Komiyama, Yusuke Miyazaki, Hiromichi Wada, Moritake Iguchi, Mitsuru Abe, Hisashi Ogawa, Masaharu Akao, Hajime Yamakage, Noriko Satoh-Asahara, Yoichi Sunagawa, Tatsuya Morimoto, Koji Hasegawa   +11 more
doaj   +1 more source

Critical Analysis of Apixaban Dose Adjustment Criteria

Clinical and Applied Thrombosis/Hemostasis, 2021
Apixaban is indicated for the prevention of ischemic stroke in non-valvular atrial fibrillation (NVAF), as well as for the prevention and treatment of venous thromboembolism (VTE).
Anh Vu PharmD, Tao T. Qu PharmD, Rachel Ryu PharmD, BCPS, Shuktika Nandkeolyar MD, Alan Jacobson MD, Lisa T. Hong PharmD, BCPS   +5 more
doaj   +1 more source

Plasma apixaban levels in Chinese patients with chronic kidney disease—Relationship with renal function and bleeding complications

Frontiers in Pharmacology, 2022
Introduction: Accumulation of apixaban in plasma is a major concern in patients with chronic kidney disease (CKD). Studies that investigated plasma apixaban level in CKD patients and its association with clinically significant events are scarce.Methods ...
Chun-fung Sin, Ka-ping Wong, Ka-ping Wong, Tsz-fu Wong, Chung-wah Siu, Desmond Y. H. Yap   +5 more
doaj   +1 more source

Population pharmacokinetics of apixaban in a real‐life hospitalized population from the OptimAT study

CPT: Pharmacometrics & Systems Pharmacology, 2023
This study aimed to characterize apixaban pharmacokinetics (PKs) and its variability in a real‐world clinical setting of hospitalized patients using a population PK (PopPK) approach. Model‐based simulations helped to identify factors that affect apixaban
Frédéric Gaspar, Jean Terrier, Samantha Favre, Pauline Gosselin, Pierre Fontana, Youssef Daali, Camille Lenoir, Caroline Flora Samer, Victoria Rollason, Jean‐Luc Reny, Chantal Csajka, Monia Guidi   +11 more
doaj   +1 more source

Apixaban as a Rare Cause of Leukocytoclastic Vasculitis

Case Reports in Rheumatology, 2020
Apixaban is a rare cause of leukocytoclastic vasculitis (LCV). To our knowledge, there is only one other reported case due to apixaban in the literature. We present a case of apixaban-induced leukocytoclastic vasculitis in a 95-year-old male. He had been
Jenna Spears, David Alexandre Chetrit, Sina Manthey, Christopher Lee, Yousif Al-Saiegh   +4 more
doaj   +1 more source

The influence of residual apixaban on bleeding complications during and after catheter ablation of atrial fibrillation

Journal of Arrhythmia, 2017
Background: The periprocedural protocol for atrial fibrillation (AF) ablation commonly includes anticoagulation therapy. Apixaban, a direct oral anticoagulant, is currently approved for clinical use; however, little is known about the effects of residual
Yutaro Mukai, Kyoichi Wada, Koji Miyamoto, Kazuki Nakagita, Mai Fujimoto, Kouichi Hosomi, Takeshi Kuwahara, Mitsutaka Takada, Kengo Kusano, Akira Oita   +9 more
doaj   +1 more source

Does amiodarone impact on apixaban levels? The effect of amiodarone on apixaban level among Thai patients with non-valvular Atrial Fibrillation.

PLoS ONE
BackgroundApixaban and amiodarone are drugs used for non-valvular atrial fibrillation (NVAF) in routine practice. The evidence about apixaban plasma levels in patients who receive apixaban with amiodarone, including bleeding outcomes, has been limited ...
Sutee Limcharoen, Sarawuth Limprasert, Pornwalai Boonmuang, Manat Pongchaidecha, Juthathip Suphanklang, Weerayuth Saelim, Wichai Santimaleeworagun, Piyarat Pimsi   +7 more
doaj   +1 more source

Carbamazepine Induction Impacting Apixaban Concentrations: A Case ReportNovel Teaching Points

CJC Open, 2020
Avoidance of apixaban with carbamazepine (CBZ) is recommended owing to an anticipated reduction in apixaban concentration, although this drug interaction is poorly described. We report a case wherein apixaban concentration was measured before and 2 weeks
Tammy J. Bungard, BSP, PharmD, R. Neil Roberts, MD   +1 more
doaj   +1 more source